JVE and ST equally contributed to: Conceptualization, Writing—original draft. SA and PG: Conceptualization, Writing—original draft. JA: Writing—review & editing, Validation, Supervision.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Xiang Y, Wu H, Li L, Ren M, Qie H, Lin A. A review of distribution and risk of pharmaceuticals and personal care products in the aquatic environment in China.Ecotoxicol Environ Saf. 2021;213:112044. [DOI] [PubMed]
Carlsson C, Johansson AK, Alvan G, Bergman K, Kühler T. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients.Sci Total Environ. 2006;364:67–87. [DOI] [PubMed]
Daughton CG. Pharmaceuticals as Environmental Pollutants: The Ramifications for Human Exposure. In: Heggenhougen HK, editor. International Encyclopedia of Public Health. Oxford: Academic Press; 2008. pp. 66–102. [DOI]
Manaia CM, Aga DS, Cytryn E, Gaze WH, Graham DW, Guo J, et al. The Complex Interplay Between Antibiotic Resistance and Pharmaceutical and Personal Care Products in the Environment.Environ Toxicol Chem. 2024;43:637–52. [DOI] [PubMed]
Tello A, Austin B, Telfer TC. Selective pressure of antibiotic pollution on bacteria of importance to public health.Environ Health Perspect. 2012;120:1100–6. [DOI] [PubMed] [PMC]
Maghsodian Z, Sanati AM, Mashifana T, Sillanpää M, Feng S, Nhat T, et al. Occurrence and Distribution of Antibiotics in the Water, Sediment, and Biota of Freshwater and Marine Environments: A Review.Antibiotics (Basel). 2022;11:1461. [DOI] [PubMed] [PMC]
Kraemer SA, Ramachandran A, Perron GG. Antibiotic Pollution in the Environment: From Microbial Ecology to Public Policy.Microorganisms. 2019;7:180. [DOI] [PubMed] [PMC]
Weatherly LM, Gosse JA. Triclosan exposure, transformation, and human health effects.J Toxicol Environ Health B Crit Rev. 2017;20:447–69. [DOI] [PubMed] [PMC]
Dutta TK, Yadav SK, Chatterjee A. Antibiotics as feed additives for livestock: human health concerns.Indian J Anim Hlth. 2019;58:121–36. [DOI]
Clardy J, Fischbach MA, Currie CR. The natural history of antibiotics.Curr Biol. 2009;19:R437–41. [DOI] [PubMed] [PMC]
Davies J. Origins and evolution of antibiotic resistance.Microbiologia. 1996;12:9–16. [PubMed]
Bielen A, Šimatović A, Kosić-Vukšić J, Senta I, Ahel M, Babić S, et al. Negative environmental impacts of antibiotic-contaminated effluents from pharmaceutical industries.Water Res. 2017;126:79–87. [DOI] [PubMed]
Lübbert C, Baars C, Dayakar A, Lippmann N, Rodloff AC, Kinzig M, et al. Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens.Infection. 2017;45:479–91. [DOI] [PubMed]
Carvalho IT, Santos L. Antibiotics in the aquatic environments: A review of the European scenario.Environ Int. 2016;94:736–57. [DOI] [PubMed]
Chaturvedi P, Shukla P, Giri BS, Chowdhary P, Chandra R, Gupta P, et al. Prevalence and hazardous impact of pharmaceutical and personal care products and antibiotics in environment: A review on emerging contaminants.Environ Res. 2021;194:110664. [DOI] [PubMed]
Conde-Cid M, Núñez-Delgado A, Fernández-Sanjurjo MJ, Álvarez-Rodríguez E, Fernández-Calviño D, Arias-Estévez M. Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks.Processes. 2020;8:1479. [DOI]
Liu X, Huang D, Lai C, Zeng G, Qin L, Zhang C, et al. Recent advances in sensors for tetracycline antibiotics and their applications.TrAC Trends Anal Chem. 2018;109:260–74. [DOI]
Parente CET, Brito EMS, Azeredo A, Meire RO, Malm O. Fluoroquinolone Antibiotics and their Interactions in Agricultural Soils – A Review.Orbital: Electron J Chem. 2019;11:42–52. [DOI]
Golsha R, Montazeri M, Razaghi N, Zade ME. Frequency of Beta-Lactamase Antibiotic Resistance Genes in Escherichia Coli and Klebsiella pneumoniae.Ethiop J Health Sci. 2021;31:663–72. [DOI] [PubMed] [PMC]
Takahashi Y, Igarashi M. Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’.J Antibiot (Tokyo). 2018;71:4–14. [DOI] [PubMed]
Ogier JM, Lockhart PJ, Burt RA. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.Hear Res. 2020;386:107870. [DOI] [PubMed]
Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics?Arch Dis Child Educ Pract Ed. 2017;102:89–93. [DOI] [PubMed]
Malin JJ, de Leeuw E. Therapeutic compounds targeting Lipid II for antibacterial purposes.Infect Drug Resist. 2019;12:2613–25. [DOI] [PubMed] [PMC]
Pathania S, Petrova-Szczasiuk K, Pentikäinen O, Singh PK. Oxazolidinones: Are they only good for the discovery of antibiotics? A worm’s eye view.J Mol Struct. 2023;1286:135630. [DOI]
Bengtsson-Palme J, Kristiansson E, Larsson DGJ. Environmental factors influencing the development and spread of antibiotic resistance.FEMS Microbiol Rev. 2018;42:fux053. [DOI] [PubMed] [PMC]
Kaplan T. The Role of Horizontal Gene Transfer in Antibiotic Resistance.Eukaryon. 2014;10:80–1.
Spagnolo F, Trujillo M, Dennehy JJ. Why Do Antibiotics Exist?mBio. 2021;12:e01966-21. [DOI] [PubMed] [PMC]
Zhuang M, Achmon Y, Cao Y, Liang X, Chen L, Wang H, et al. Distribution of antibiotic resistance genes in the environment.Environ Pollut. 2021;285:117402. [DOI] [PubMed]
Larsson DGJ, Flach CF. Antibiotic resistance in the environment.Nat Rev Microbiol. 2022;20:257–69. [DOI] [PubMed] [PMC]
von Wintersdorff CJ, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer.Front Microbiol. 2016;7:173. [DOI] [PubMed] [PMC]
Bello-López JM, Cabrero-Martínez OA, Ibáñez-Cervantes G, Hernández-Cortez C, Pelcastre-Rodríguez LI, Gonzalez-Avila LU, et al. Horizontal Gene Transfer and Its Association with Antibiotic Resistance in the Genus Aeromonas spp.Microorganisms. 2019;7:363. [DOI] [PubMed] [PMC]
Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, et al. Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis.PLoS One. 2020;15:e0227139. [DOI] [PubMed] [PMC]
Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.PLoS One. 2015;10:e0127448. [DOI] [PubMed] [PMC]
Lebeaux RM, Madan JC, Nguyen QP, Coker MO, Dade EF, Moroishi Y, et al. Impact of antibiotics on off-target infant gut microbiota and resistance genes in cohort studies.Pediatr Res. 2022;92:1757–66. [DOI] [PubMed] [PMC]
Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.J Chemother. 2017;29:2–9. [DOI] [PubMed]
Manyahi J, Kibwana U, Mgimba E, Majigo M. Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania.PLoS One. 2020;15:e0220424. [DOI] [PubMed] [PMC]
Magira EE, Islam S, Niederman MS. Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome.Med Intensiva (Engl Ed). 2018;42:225–34. [DOI] [PubMed]
Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology.J Hepatol. 2016;65:1043–54. [DOI] [PubMed]
Danner MC, Robertson A, Behrends V, Reiss J. Antibiotic pollution in surface fresh waters: Occurrence and effects.Sci Total Environ. 2019;664:793–804. [DOI] [PubMed]
Gothwal R, Shashidhar T. Antibiotic Pollution in the Environment: A Review.Clean Soil Air Water. 2015;43:479–89. [DOI]
Kulik K, Lenart-Boroń A, Wyrzykowska K. Impact of Antibiotic Pollution on the Bacterial Population within Surface Water with Special Focus on Mountain Rivers.Water. 2023;15:975. [DOI]
Seifrtová M, Nováková L, Lino C, Pena A, Solich P. An overview of analytical methodologies for the determination of antibiotics in environmental waters.Anal Chim Acta. 2009;649:158–79. [DOI] [PubMed]
Zhou HC, Long JR, Yaghi OM. Introduction to metal-organic frameworks.Chem Rev. 2012;112:673–4. [DOI] [PubMed]
Szymańska U, Wiergowski M, Sołtyszewski I, Kuzemko J, Wiergowska G, Woźniak MK. Presence of antibiotics in the aquatic environment in Europe and their analytical monitoring: Recent trends and perspectives.Microchem J. 2019;147:729–40. [DOI]
Massé DI, Saady NM, Gilbert Y. Potential of Biological Processes to Eliminate Antibiotics in Livestock Manure: An Overview.Animals (Basel). 2014;4:146–63. [DOI] [PubMed] [PMC]
Šimatović A, Udiković-Kolić N. Antibiotic Resistance in Pharmaceutical Industry Effluents and Effluent-Impacted Environments. In: Manaia CM, Donner E, Vaz-Moreira I, Hong P, editors. Antibiotic Resistance in the Environment : A Worldwide Overview. Cham: Springer International Publishing; 2020. pp. 101–22. [DOI]
Auguet O, Pijuan M, Borrego CM, Rodriguez-Mozaz S, Triadó-Margarit X, Giustina SVD, et al. Sewers as potential reservoirs of antibiotic resistance.Sci Total Environ. 2017;605–606:1047–54. [DOI] [PubMed]
Amarasiri M, Sano D, Suzuki S. Understanding human health risks caused by antibiotic resistant bacteria (ARB) and antibiotic resistance genes (ARG) in water environments: Current knowledge and questions to be answered.Crit Rev Environ Sci Technol. 2020;50:2016–59. [DOI]
Anh HQ, Le TPQ, Da Le N, Lu XX, Duong TT, Garnier J, et al. Antibiotics in surface water of East and Southeast Asian countries: A focused review on contamination status, pollution sources, potential risks, and future perspectives.Sci Total Environ. 2021;764:142865. [DOI] [PubMed]
Han QF, Zhao S, Zhang XR, Wang XL, Song C, Wang SG. Distribution, combined pollution and risk assessment of antibiotics in typical marine aquaculture farms surrounding the Yellow Sea, North China.Environ Int. 2020;138:105551. [DOI] [PubMed]
Hernández F, Calısto-Ulloa N, Gómez-Fuentes C, Gómez M, Ferrer J, González-Rocha G, et al. Occurrence of antibiotics and bacterial resistance in wastewater and sea water from the Antarctic.J Hazard Mater. 2019;363:447–56. [DOI] [PubMed]
Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK.Water Res. 2008;42:3498–518. [DOI] [PubMed]
Flint S, Markle T, Thompson S, Wallace E. Bisphenol A exposure, effects, and policy: a wildlife perspective.J Environ Manage. 2012;104:19–34. [DOI] [PubMed]
Tijani JO, Fatoba OO, Petrik LF. A Review of Pharmaceuticals and Endocrine-Disrupting Compounds: Sources, Effects, Removal, and Detections.Water Air Soil Pollut. 2013;224:1770. [DOI]
Paul G, Binitha RN, Sunny F. Fish short-term reproductive assay for evaluating the estrogenic property of a commonly used antioxidant, butylated hydroxyanisole.Curr Sci. 2018;115:1584–7.
Gill WB, Schumacher GF, Bibbo M, Straus FH 2nd, Schoenberg HW. Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities.J Urol. 1979;122:36–9. [DOI] [PubMed]
Eldridge JC, Fleenor-Heyser DG, Extrom PC, Wetzel LT, Breckenridge CB, Gillis JH, et al. Short-term effects of chlorotriazines on estrus in female Sprague-Dawley and Fischer 344 rats.J Toxicol Environ Health. 1994;43:155–67. [DOI] [PubMed]
Connor K, Howell J, Chen I, Liu H, Berhane K, Sciarretta C, et al. Failure of chloro-S-triazine-derived compounds to induce estrogen receptor-mediated responses in vivo and in vitro.Fundam Appl Toxicol. 1996;30:93–101. [DOI] [PubMed]
Cooper RL, Stoker TE, Tyrey L, Goldman JM, McElroy WK. Atrazine disrupts the hypothalamic control of pituitary-ovarian function.Toxicol Sci. 2000;53:297–307. [DOI] [PubMed]
Li J, Li S, Bai C, Liu H, Gramatica P. Structural requirements of 3-carboxyl-4(1H)-quinolones as potential antimalarials from 2D and 3D QSAR analysis.J Mol Graph Model. 2013;44:266–77. [DOI] [PubMed]
Lin YC, Lin JF, Wen SI, Yang SC, Tsai TF, Chen HE, et al. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.Kaohsiung J Med Sci. 2017;33:215–23. [DOI] [PubMed]
Halaby MJ, Kastein BK, Yang DQ. Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt.Biochem Biophys Res Commun. 2013;435:708–13. [DOI] [PubMed]
Okanlawon AO, Ashiru OA. Effect of chloroquine on oestrus cycle and ovulation in cyclic rats.J Appl Toxicol. 1992;12:45–8. [DOI] [PubMed]
Hughes SF, Haney AF, Hughes CL Jr. Use of human cumulus granulosa cells for in vitro screening of reproductive toxicants.Reprod Toxicol. 1990;4:11–5. [DOI] [PubMed]
Teaff NL, Savoy-Moore RT. Human granulosa-luteal cell response to vinblastine exposure in vitro.Reprod Toxicol. 1991;5:371–7. [DOI] [PubMed]
Hansmann I. Chromosome aberrations in metaphase II-oocytes. Stage sensitivity in the mouse oogenesis to amethopterin and cyclophosphamide.Mutat Res. 1974;22:175–91. [DOI] [PubMed]
Jarrell JF, Bodo L, Younglai EV, Barr RD, O’Connell GJ. The short-term reproductive toxicity of cyclophosphamide in the female rat.Reprod Toxicol. 1991;5:481–5. [DOI] [PubMed]
U. S. EPA. Special Report on Environmental Endocrine Disruption: An Effects Assessment and Analysis. Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum; 1997. Report No.: 630/R-96/012.
Jin UH, Lee SO, Safe S. Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.J Pharmacol Exp Ther. 2012;343:333–41. [DOI] [PubMed] [PMC]
Ingerslev F, Vaclavik E, Halling-Sørensen B. Pharmaceuticals and personal care products - A source of endocrine disruption in the environment?Pure Appl Chem. 2003;75:1881–93. [DOI]
Boxall ABA. The environmental side effects of medication.EMBO Rep. 2004;5:1110–6. [DOI] [PubMed] [PMC]
Al-Odaini N, Zakaria MP, Yaziz MI, Surif S. Detecting Human Pharmaceutical Pollutants in Malaysian Aquatic Environment: A new challenge for water quality management.In: Contemporary environmental quality management in Malaysia and selected countries. UPM Press; 2011.
Jones OA, Voulvoulis N, Lester JN. Human pharmaceuticals in the aquatic environment a review.Environ Technol. 2001;22:1383–94. [DOI] [PubMed]
Chen J, Ying GG, Wei XD, Liu YS, Liu SS, Hu LX, et al. Removal of antibiotics and antibiotic resistance genes from domestic sewage by constructed wetlands: Effect of flow configuration and plant species.Sci Total Environ. 2016;571:974–82. [DOI] [PubMed]
Ziylan A, Ince NH. The occurrence and fate of anti-inflammatory and analgesic pharmaceuticals in sewage and fresh water: treatability by conventional and non-conventional processes.J Hazard Mater. 2011;187:24–36. [DOI] [PubMed]
Halling-Sørensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lützhøft HC, Jørgensen SE. Occurrence, fate and effects of pharmaceutical substances in the environment- a review.Chemosphere. 1998;36:357–93. [DOI] [PubMed]
Mauro M, Lazzara V, Arizza V, Luparello C, Ferrantelli V, Cammilleri G, et al. Human Drug Pollution in the Aquatic System: The Biochemical Responses of Danio rerio Adults.Biology (Basel). 2021;10:1064. [DOI] [PubMed] [PMC]
Valdez-Carrillo M, Abrell L, Ramírez-Hernández J, Reyes-López JA, Carreón-Diazconti C. Pharmaceuticals as emerging contaminants in the aquatic environment of Latin America: a review.Environ Sci Pollut Res Int. 2020;27:44863–91. [DOI] [PubMed]
Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs.Epilepsy Behav. 2004;5:60–5. [DOI] [PubMed]
Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, et al. Adverse drug events in high risk older outpatients.J Am Geriatr Soc. 1997;45:945–8. [DOI] [PubMed]
Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects.Ochsner J. 2013;13:214–23. [PubMed] [PMC]
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med. 1999;341:1865–73. [DOI] [PubMed]
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.AIDS. 2001;15:71–5. [DOI] [PubMed]
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS. 2004;18:2391–400. [PubMed]
Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.Clin Pharmacol Ther. 2003;73:20–30. [DOI] [PubMed]
de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation.N Engl J Med. 1987;317:861–6. [DOI] [PubMed]
Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis.Arch Clin Neuropsychol. 2018;33:901–11. [DOI] [PubMed]
Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use.Curr Pharm Des. 2002;8:45–58. [DOI] [PubMed]
Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population.Crit Care Med. 2009;37:177–83. [DOI] [PubMed] [PMC]
Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU).JAMA. 2001;286:2703–10. [DOI] [PubMed]
Paulus MP, Stewart JL. Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.JAMA Psychiatry. 2020;77:959–66. [DOI] [PubMed] [PMC]
Zhao YL, Zhao W, Liu M, Liu L, Wang Y. TBHQ-Overview of Multiple Mechanisms against Oxidative Stress for Attenuating Methamphetamine-Induced Neurotoxicity.Oxid Med Cell Longev. 2020;2020:8874304. [DOI] [PubMed] [PMC]
Yang X, Wang Y, Li Q, Zhong Y, Chen L, Du Y, et al. The Main Molecular Mechanisms Underlying Methamphetamine- Induced Neurotoxicity and Implications for Pharmacological Treatment.Front Mol Neurosci. 2018;11:186. [DOI] [PubMed] [PMC]
Lappin JM, Sara GE. Psychostimulant use and the brain.Addiction. 2019;114:2065–77. [DOI] [PubMed]
Wearne TA, Cornish JL. A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.Front Psychiatry. 2018;9:491. [DOI] [PubMed] [PMC]
Jayanthi S, Daiwile AP, Cadet JL. Neurotoxicity of methamphetamine: Main effects and mechanisms.Exp Neurol. 2021;344:113795. [DOI] [PubMed] [PMC]
Deng X, Ladenheim B, Jayanthi S, Cadet JL. Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb.Biol Psychiatry. 2007;61:1235–43. [DOI] [PubMed]
Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, Cai NS, et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis.Proc Natl Acad Sci U S A. 2005;102:868–73. [DOI] [PubMed] [PMC]
Armstrong BD, Noguchi KK. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats.Neurotoxicology. 2004;25:905–14. [DOI] [PubMed]
Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration.Int Rev Neurobiol. 2009;88:101–19. [DOI] [PubMed] [PMC]
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings.Drug Alcohol Depend. 2013;129:167–79. [DOI] [PubMed]
Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs.Drug Alcohol Depend. 2012;120:35–40. [DOI] [PubMed]
Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment.Drug Alcohol Depend. 2015;146:30–8. [DOI] [PubMed] [PMC]
Todd G, Pearson-Dennett V, Wilcox RA, Chau MT, Thoirs K, Thewlis D, et al. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism.Parkinsonism Relat Disord. 2016;25:27–32. [DOI] [PubMed]
Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.Am J Psychiatry. 2001;158:377–82. [DOI] [PubMed]
Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms.Am J Psychiatry. 2003;160:1699–701. [DOI] [PubMed]
Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers.Arch Gen Psychiatry. 2006;63:90–100. [DOI] [PubMed]
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine.J Neurosci. 2004;24:6028–36. [DOI] [PubMed] [PMC]
Hall MG, Alhassoon OM, Stern MJ, Wollman SC, Kimmel CL, Perez-Figueroa A, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis.Am J Drug Alcohol Abuse. 2015;41:290–9. [DOI] [PubMed]
Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.Mol Pharmacol. 1978;14:633–43. [PubMed]
Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress.J Pharmacol Exp Ther. 1998;287:107–14. [PubMed]
LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.J Neurosci. 1999;19:1484–91. [DOI] [PubMed] [PMC]
Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers.J Neurosci. 2008;28:5756–61. [DOI] [PubMed] [PMC]
Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, et al. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat.PLoS One. 2010;5:e8790. [DOI] [PubMed] [PMC]
McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, et al. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.J Pharmacol Exp Ther. 2012;340:295–303. [DOI] [PubMed] [PMC]
Xu E, Liu J, Liu H, Wang X, Xiong H. Role of microglia in methamphetamine-induced neurotoxicity.Int J Physiol Pathophysiol Pharmacol. 2017;9:84–100. [PubMed] [PMC]
Tahmasebinia F, Pourgholaminejad A. The role of Th17 cells in auto-inflammatory neurological disorders.Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:408–16. [DOI] [PubMed]
Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review.Neurotox Res. 2005;8:199–206. [DOI] [PubMed]
Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.Neurotox Res. 2007;11:183–202. [DOI] [PubMed]
Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death.Brain Res Rev. 2009;60:379–407. [DOI] [PubMed] [PMC]
Cadet JL, McCoy MT, Ladenheim B. Distinct gene expression signatures in the striata of wild-type and heterozygous c-fos knockout mice following methamphetamine administration: evidence from cDNA array analyses.Synapse. 2002;44:211–26. [DOI] [PubMed]
Cadet JL, Jayanthi S, McCoy MT, Beauvais G, Cai NS. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.CNS Neurol Disord Drug Targets. 2010;9:526–38. [DOI] [PubMed] [PMC]
Martin TA, Jayanthi S, McCoy MT, Brannock C, Ladenheim B, Garrett T, et al. Methamphetamine causes differential alterations in gene expression and patterns of histone acetylation/hypoacetylation in the rat nucleus accumbens.PLoS One. 2012;7:e34236. [DOI] [PubMed] [PMC]
Beauvais G, Jayanthi S, McCoy MT, Ladenheim B, Cadet JL. Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum.Brain Res. 2010;1318:1–10. [DOI] [PubMed] [PMC]
O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.J Neurosci. 1988;8:2788–803. [DOI] [PubMed] [PMC]
McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): a controlled study in humans.Neuropsychopharmacology. 1994;10:129–38. [DOI] [PubMed]
Jevtovic-Todorovic V, Absalom AR, Blomgren K, Brambrink A, Crosby G, Culley DJ, et al. Anaesthetic neurotoxicity and neuroplasticity: an expert group report and statement based on the BJA Salzburg Seminar.Br J Anaesth. 2013;111:143–51. [DOI] [PubMed] [PMC]
Creeley C, Dikranian K, Dissen G, Martin L, Olney J, Brambrink A. Propofol-induced apoptosis of neurones and oligodendrocytes in fetal and neonatal rhesus macaque brain.Br J Anaesth. 2013;110:i29–38. [DOI] [PubMed] [PMC]
Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, Martin LD, et al. Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain.Anesthesiology. 2012;116:372–84. [DOI] [PubMed] [PMC]
Flick RP, Katusic SK, Colligan RC, Wilder RT, Voigt RG, Olson MD, et al. Cognitive and behavioral outcomes after early exposure to anesthesia and surgery.Pediatrics. 2011;128:e1053–61. [DOI] [PubMed] [PMC]
Ready LB, Plumer MH, Haschke RH, Austin E, Sumi SM. Neurotoxicity of intrathecal local anesthetics in rabbits.Anesthesiology. 1985;63:364–70. [PubMed]
Johnson ME, Uhl CB. Toxic Elevation of Cytoplasmic Calcium by High Dose Lidocaine in a Neuronal Cell Line.Reg Anesth Pain Med. 1997;22:68. [DOI]
Hodgson PS, Neal JM, Pollock JE, Liu SS. The neurotoxicity of drugs given intrathecally (spinal).Anesth Analg. 1999;88:797–809. [DOI] [PubMed]
Schneider M, Ettlin T, Kaufmann M, Schumacher P, Urwyler A, Hampl K, et al. Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine.Anesth Analg. 1993;76:1154–7. [DOI] [PubMed]
Pollock JE, Liu SS, Neal JM, Stephenson CA. Dilution of spinal lidocaine does not alter the incidence of transient neurologic symptoms.Anesthesiology. 1999;90:445–50. [DOI] [PubMed]
Hampl KF, Heinzmann-Wiedmer S, Luginbuehl I, Harms C, Seeberger M, Schneider MC, et al. Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.Anesthesiology. 1998;88:629–33. [DOI] [PubMed]
Horlocker TT, McGregor DG, Matsushige DK, Schroeder DR, Besse JA. A retrospective review of 4767 consecutive spinal anesthetics: central nervous system complications.Anesth Analg. 1997;84:578–84. [DOI] [PubMed]
Auroy Y, Narchi P, Messiah A, Litt L, Rouvier B, Samii K. Serious complications related to regional anesthesia: results of a prospective survey in France.Anesthesiology. 1997;87:479–86. [DOI] [PubMed]
Dripps RD, Vandam LD. Long-term follow-up of patients who received 10,098 spinal anesthetics: failure to discover major neurological sequelae.J Am Med Assoc. 1954;156:1486–91. [DOI] [PubMed]
Phillips OC, Ebner H, Nelson AT, Black MH. Neurologic complications following spinal anesthesia with lidocaine: a prospective review of 10,440 cases.Anesthesiology. 1969;30:284–9. [DOI] [PubMed]
Aromaa U, Lahdensuu M, Cozanitis DA. Severe complications associated with epidural and spinal anaesthesias in Finland 1987–1993. A study based on patient insurance claims.Acta Anaesthesiol Scand. 1997;41:445–52. [DOI] [PubMed]
